Skin Cancer Clinical Trials
Melanoma
Learn More About Melanoma
For general information on melanoma (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| CP-AU-007-01 | Melanoma | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| DCSZ11-101 | Melanoma | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| PTT-4256-01 | Melanoma | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| AMT-253-01 | Melanoma | First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti MUC18 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics (Australia) Pty Ltd | NCT05906862 | Enquire Now |
| NST-628-001 | Melanoma | A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors | Targeted | MAPK pathway mutated/dependent advanced solid tumors. | Open - Recruiting | Nested Therapeutics, Inc | NCT06326411 | Enquire Now |
| HMBD-001-103 | Melanoma | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanised IgG1 anti-HER3 monoclonal antibody | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| ON-5001 | Melanoma | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesion | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |